is the fda stopping compounded tirzepatide says compounding pharmacies can keep making weight-loss med tirzepatide, for now FDA Announces End To Compounded

When compared with placebo or other therapies, GLP-1 agonists were associated with an increased risk of biliary disease [23]: Overall biliary disease: RR 1.37(95% CI 1.231.52) Cholelithiasis: RR 1.27 (95% CI 1.101.47) Cholecystitis: RR 1.36 (95% CI 1.141.62) Mechanisms: Reduced gallbladder motility Rapid weight loss increased cholesterol saturation and gallstone formation

People will be healthier

"It has been quite difficult, to be honest with you, trying to get it for our patients who are diabetic, who need it, but then also for our patients who have obesity, who need it as well," Shelly says.

Zerbo O, Losif AM, Walker C, Ozonoff S, Hansen RL, Hertz-Picciotto